Santarus' CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Santarus, Inc. (SNTS)

Bank of America Merrill Lynch 2012 Health Care Conference Call

May 15, 2012 5:20 pm ET

Executives

Gerald T. Proehl – President and Chief Executive Officer

Wendell Wierenga – Executive Vice President, Research and Development

Debra P. Crawford – Senior Vice President, Chief Financial Officer, Treasurer and Secretary

Presentation

[Starts Abruptly]

Biotech team at Bank of America Merrill Lynch. Our next presenting company is Santarus, and it’s my pleasure to introduce Executive Vice President of R&D, Wendell Wierenga.

Wendell Wierenga

Thank you very much for the introduction and the opportunity to present Santarus at Bank of America conference. I also need to remind the audience that we are making forward-looking statements based on our beliefs and assumptions that are currently available to us. I also want to note that, Debbie Crawford is also here today with myself representing Santarus, and we look forward to participating in the question-and-answer as the presentation winds up.

Debbie Crawford is the CFO of Santarus. Santarus represents in my view, a very compelling investment rationale for three reasons, number one, we have growing revenues on our exclusive marketed products; number two, we are focusing on physician specialists, and number three, we have a balanced portfolio, balanced in the sense that its marketed as well as late stage development programs and even programs that are longer term in terms of the development horizon and ultimate commercialization, and we’re balancing our SG&A and R&D investment to not only capitalize on the near-term, but also to achieve sustained growth in the longer term.

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus

Insider Trading Alert - Santarus And 4 Others Traded By Insiders